We've found
25,125
archived clinical trials in
Diabetes
We've found
25,125
archived clinical trials in
Diabetes
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
Updated: 4/27/2016
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
Status: Enrolling
Updated: 4/27/2016
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
Updated: 4/27/2016
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
Status: Enrolling
Updated: 4/27/2016
Click here to add this to my saved trials

The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
Updated: 4/27/2016
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
Status: Enrolling
Updated: 4/27/2016
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
Updated: 4/27/2016
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
Status: Enrolling
Updated: 4/27/2016
Click here to add this to my saved trials

Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus
Updated: 4/27/2016
Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 4/27/2016
Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus
Updated: 4/27/2016
Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 4/27/2016
Click here to add this to my saved trials

Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men
Updated: 5/2/2016
Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men
Status: Enrolling
Updated: 5/2/2016
Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men
Updated: 5/2/2016
Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Updated: 5/2/2016
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Click here to add this to my saved trials

Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Click here to add this to my saved trials

Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Click here to add this to my saved trials

Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Click here to add this to my saved trials

Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Click here to add this to my saved trials

Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Click here to add this to my saved trials

Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Click here to add this to my saved trials

Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Click here to add this to my saved trials

Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Click here to add this to my saved trials

Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Updated: 5/9/2016
Click here to add this to my saved trials

Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Updated: 5/10/2016
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Status: Enrolling
Updated: 5/10/2016
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Updated: 5/10/2016
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Status: Enrolling
Updated: 5/10/2016
Click here to add this to my saved trials

Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Updated: 5/10/2016
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Status: Enrolling
Updated: 5/10/2016
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Updated: 5/10/2016
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Status: Enrolling
Updated: 5/10/2016
Click here to add this to my saved trials

Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide
Status: Enrolling
Updated: 5/10/2016
Updated: 5/10/2016
Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide
Status: Enrolling
Updated: 5/10/2016
Updated: 5/10/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Updated: 5/12/2016
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

Feet First: Promoting Physical Activity Among People With Diabetes Mellitus and Insensate Feet
Updated: 5/12/2016
Feet First: Increasing Activity Without Increasing the Risk of Foot Ulcers in People With Diabetes and Insensate Feet
Status: Enrolling
Updated: 5/12/2016
Feet First: Promoting Physical Activity Among People With Diabetes Mellitus and Insensate Feet
Updated: 5/12/2016
Feet First: Increasing Activity Without Increasing the Risk of Foot Ulcers in People With Diabetes and Insensate Feet
Status: Enrolling
Updated: 5/12/2016
Click here to add this to my saved trials

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation
Updated: 5/17/2016
A Single-Center, Randomized, Open-Label, 2-Period Complete Crossover Study to Compare the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation in Healthy Adult Subjects
Status: Enrolling
Updated: 5/17/2016
A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation
Updated: 5/17/2016
A Single-Center, Randomized, Open-Label, 2-Period Complete Crossover Study to Compare the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation in Healthy Adult Subjects
Status: Enrolling
Updated: 5/17/2016
Click here to add this to my saved trials

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
Updated: 5/18/2016
A Randomized, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study Assessing the Safety of SAR342434 and Humalog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)
Status: Enrolling
Updated: 5/18/2016
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
Updated: 5/18/2016
A Randomized, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study Assessing the Safety of SAR342434 and Humalog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)
Status: Enrolling
Updated: 5/18/2016
Click here to add this to my saved trials

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
Updated: 5/18/2016
A Randomized, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study Assessing the Safety of SAR342434 and Humalog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)
Status: Enrolling
Updated: 5/18/2016
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
Updated: 5/18/2016
A Randomized, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study Assessing the Safety of SAR342434 and Humalog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)
Status: Enrolling
Updated: 5/18/2016
Click here to add this to my saved trials
